JMP Securities Reaffirms Their Buy Rating on Ocular Therapeutix (OCUL)

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Ocular Therapeutix (OCULResearch Report) today and set a price target of $25.00. The company’s shares closed yesterday at $5.28.

Wolleben covers the Healthcare sector, focusing on stocks such as Altimmune, Intercept Pharma, and Ocular Therapeutix. According to TipRanks, Wolleben has an average return of -8.3% and a 35.56% success rate on recommended stocks.

Currently, the analyst consensus on Ocular Therapeutix is a Strong Buy with an average price target of $16.67.

See the top stocks recommended by analysts >>

Based on Ocular Therapeutix’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $12.27 million and a GAAP net loss of $18.77 million. In comparison, last year the company earned a revenue of $11.72 million and had a GAAP net loss of $8.48 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More